More about

Leukemia

News
August 10, 2021
2 min read
Save

Patients with certain blood cancers may be at risk for breakthrough COVID-19 infections

Patients with certain blood cancers may be at risk for breakthrough COVID-19 infections

Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.

News
August 10, 2021
4 min read
Save

One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells

One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells

CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.

News
August 02, 2021
1 min read
Save

Zanubrutinib extends PFS in treatment-naive CLL

Zanubrutinib extends PFS in treatment-naive CLL

Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.

News
August 02, 2021
1 min read
Save

Ivosidenib regimen extends EFS in IDH1-mutated AML

Ivosidenib regimen extends EFS in <i>IDH1</i>-mutated AML

The addition of ivosidenib tablets to azacitidine prolonged EFS among patients with previously untreated IDH1-mutated acute myeloid leukemia, according to topline data released by the agent’s manufacturer.

News
July 30, 2021
1 min read
Save

FDA grants fast track designation to eryaspase for hypersensitive ALL

FDA grants fast track designation to eryaspase for hypersensitive ALL

The FDA granted fast track designation to eryaspase for treatment of patients with acute lymphoblastic leukemia who developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

News
July 22, 2021
2 min read
Save

Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia

Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia

Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.

News
July 21, 2021
7 min read
Save

Immunization in cancer survivors: Optimizing response, minimizing risk

Immunization in cancer survivors: Optimizing response, minimizing risk

The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.

News
July 20, 2021
4 min read
Save

New CAR T-cell therapy uses shorter linker, leading to more potent therapy for ALL

New CAR T-cell therapy uses shorter linker, leading to more potent therapy for ALL

CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.

News
July 19, 2021
3 min read
Save

ASH to present honorific awards

ASH to present honorific awards

ASH will present honorific awards to several hematologists during this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

News
July 11, 2021
1 min read
Save

Children’s Hospital of Philadelphia appoints leukemia specialist as section chief

Children&rsquo;s Hospital of Philadelphia appoints leukemia specialist as section chief

Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.

View more